03

  • Ethics review needed for AI use in health care

    In a perspective piece, Stanford researchers discuss the ethical implications of using machine-learning tools in making health care decisions for patients.

  • Symposium to tackle AI balance in medicine

    The Presence Center is hosting a daylong symposium April 17 on issues surrounding humans and machines in medicine.

  • Neuroanatomy lab bridges virtual reality, OR

    Stanford’s Department of Neurosurgery has a new anatomy lab next door to its virtual reality center. Together, the labs are a valuable resource for trainees and surgeons alike.

  • Exome sequencing program launched

    The Clinical Genomics Program, which began as a pilot program a few years ago, offers whole-exome sequencing and analysis to patients with undiagnosed genetic diseases.

  • Grants announced to investigate IBD

    Eight Stanford Medicine researchers have received grants from the Kenneth Rainin Foundation to investigate inflammatory bowel disease.

  • Predicting success of lung cancer drug

    With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumors, according to researchers at Stanford.

  • Medicare’s blame game

    A Stanford researcher and his colleague got access to data showing the inner workings of an influential committee advising Medicare. They found that bias among its members has different effects from what critics claim.

  • Misbehaving cells predict relapse in leukemia

    Analyzing individual cancer cells has enabled Stanford researchers to identify the small population of cells that spur relapse in some children with leukemia.

  • CRISPR helps reveal drug targets for ALS

    Through genome editing, scientists at Stanford have pinpointed genes that reveal mechanistic details of ALS and may even protect against the degeneration of neurons.

  • Reducing side effects of a cancer therapy

    Stanford scientists created an odd couple: a modified version of an immune-signaling protein and a coordinately modified receptor for this protein. The two bind only to each other, easing an advanced anti-cancer therapy’s side effects.